Document is current

Article History

Received: 17 January 2025

Accepted: 10 February 2025

First Online: 22 March 2025

Declarations

:

: H.C.R. received consulting and lecture fees from Abbvie, Lilly, Janssen, Roche, Novartis, Bristol Myers Squibb, AstraZeneca, Vertex and Merck. H.C.R. received research funding from AstraZeneca and Gilead Pharmaceuticals. H.C.R. is a co-founder of CDL Therapeutics GmbH. T.R. is co-founder of mycor GmbH, a company developing AI-based algorithms for the detection of cardiac amyloidosis. A.C. received consulting and/or lecture fees from Alexion, Alnylam, Amgen, GSK, Janssen, Pfizer, Sanofi and Takeda and travel and congress participation grants from Janssen. S.O. received travel and congress participation grants from Janssen. L.M. reports personal fees from Bayer, Alnylam, AstraZeneca, Bristol Myers Squibb, Pfizer, IFFM e.V. and from Bund der Niedergelassenen Kardiologen (BNK) outside of the submitted work. S.O.S. received research support from Janssen, Prothena and Sanofi, participation in advisory board for Janssen, Telix, Sobo and Prothena, received honoraria from Janssen, Takeda, Pfizer and Prothena, travel and congress participation grants from Janssen, Prothena, Celgene, Binding Site and Jazz. U.H. received honorarium for talks: Janssen, Pfizer, Alnylam, Akcea. Financial support for congress participation: Janssen, Prothena, Pfizer. Advisory Boards: Pfizer, Prothena, Janssen. Financial sponsoring of Amyloidosis Registry: Prothena, Janssen. The remaining authors declare no competing financial interests.

: Ethical approval for this study was obtained from the ethics committee of the Medical Faculty, University of Duisburg-Essen, approval number 20-9458 BO.